Path ID: DB00806_MESH_D016491_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D010431 | Pentoxifylline | Drug |
| UniProt:Q14432 | cGMP-inhibited 3’,5’-cyclic phosphodiesterase A | Protein |
| MESH:D000242 | Cyclic AMP | ChemicalSubstance |
| reactome:R-HSA-2162123 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | BiologicalProcess |
| MESH:D013928 | Thromboxane A2 | ChemicalSubstance |
| GO:0070527 | Platelet aggregation | BiologicalProcess |
| UniProt:Q13370 | cGMP-inhibited 3’,5’-cyclic phosphodiesterase B | Protein |
| InterPro:IPR043371 | cAMP-specific 3’,5’-cyclic phosphodiesterase 4 | GeneFamily |
| UniProt:P29274 | Adenosine receptor A2a | Protein |
| GO:0004016 | Adenylate cyclase activity | MolecularActivity |
| GO:0010737 | Protein kinase A signaling | BiologicalProcess |
| GO:0071159 | NF-kappaB complex | CellularComponent |
| GO:0032612 | Interleukin-1 production | BiologicalProcess |
| GO:0032635 | Interleukin-6 production | BiologicalProcess |
| UniProt:P05362 | Intercellular adhesion molecule 1 | Protein |
| UniProt:P19320 | Vascular cell adhesion protein 1 | Protein |
| UniProt:P02741 | C-reactive protein | Protein |
| GO:0006954 | Inflammatory response | BiologicalProcess |
| MESH:D016491 | Peripheral vascular disease | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Pentoxifylline | DECREASES ACTIVITY OF | Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase A |
| Pentoxifylline | DECREASES ACTIVITY OF | Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase B |
| Pentoxifylline | DECREASES ACTIVITY OF | Camp-Specific 3’,5’-Cyclic Phosphodiesterase 4 |
| Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase A | DECREASES ABUNDANCE OF | Cyclic Amp |
| Cyclic Amp | NEGATIVELY REGULATES | Synthesis Of Prostaglandins (Pg) And Thromboxanes (Tx) |
| Synthesis Of Prostaglandins (Pg) And Thromboxanes (Tx) | INCREASES ABUNDANCE OF | Thromboxane A2 |
| Thromboxane A2 | POSITIVELY REGULATES | Platelet Aggregation |
| Platelet Aggregation | OCCURS IN | Peripheral Vascular Disease |
| Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase B | DECREASES ABUNDANCE OF | Cyclic Amp |
| Camp-Specific 3’,5’-Cyclic Phosphodiesterase 4 | DECREASES ABUNDANCE OF | Cyclic Amp |
| Pentoxifylline | INCREASES ACTIVITY OF | Adenosine Receptor A2A |
| Adenosine Receptor A2A | POSITIVELY REGULATES | Adenylate Cyclase Activity |
| Adenylate Cyclase Activity | INCREASES ABUNDANCE OF | Cyclic Amp |
| Cyclic Amp | POSITIVELY REGULATES | Protein Kinase A Signaling |
| Protein Kinase A Signaling | NEGATIVELY REGULATES | Nf-Kappab Complex |
| Nf-Kappab Complex | POSITIVELY REGULATES | Interleukin-1 Production |
| Nf-Kappab Complex | POSITIVELY REGULATES | Interleukin-6 Production |
| Nf-Kappab Complex | INCREASES ACTIVITY OF | Intercellular Adhesion Molecule 1 |
| Nf-Kappab Complex | INCREASES ACTIVITY OF | Vascular Cell Adhesion Protein 1 |
| Nf-Kappab Complex | INCREASES ACTIVITY OF | C-Reactive Protein |
| Interleukin-1 Production | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Interleukin-6 Production | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Intercellular Adhesion Molecule 1 | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Vascular Cell Adhesion Protein 1 | POSITIVELY CORRELATED WITH | Inflammatory Response |
| C-Reactive Protein | POSITIVELY CORRELATED WITH | Inflammatory Response |
| Inflammatory Response | CONTRIBUTES TO | Peripheral Vascular Disease |
Reference: